Literature DB >> 12372902

Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes.

Richard Yang1, John A Hey, Robert Aslanian, Charles A Rizzo.   

Abstract

Optical difference spectroscopy was used to identify and quantify human adrenal microsomal and mitochondrial cytochrome P450 enzyme interactions with the histamine H(3) receptor antagonists thioperamide, clobenpropit and ciproxifan. Addition of these structurally diverse imidazole H(3) receptor antagonists to cytochrome-P450-containing human adrenal microsomal and mitochondrial preparations resulted in concentration-dependent type II optical difference spectra. Respective spectral dissociation constants (K(S)) for the drug interactions with human adrenal microsomal and mitochondrial cytochrome P450 were 1.5 and 1.6 micromol/l for thioperamide, 3.1 and 0.28 micromol/l for clobenpropit and 0.10 and 0.11 micromol/l for ciproxifan. The three compounds demonstrated a similar activity profile in cytochrome-P450-containing bovine adrenal microsomal and mitochondrial preparations. Findings indicate direct coordination of these imidazole-containing H(3) receptor antagonists with the heme moiety of human adrenal cytochrome P450 isozymes. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12372902     DOI: 10.1159/000063794

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

1.  Detection of multiple H3 receptor affinity states utilizing [3H]A-349821, a novel, selective, non-imidazole histamine H3 receptor inverse agonist radioligand.

Authors:  David G Witte; Betty Bei Yao; Thomas R Miller; Tracy L Carr; Steven Cassar; Rahul Sharma; Ramin Faghih; Bruce W Surber; Timothy A Esbenshade; Arthur A Hancock; Kathleen M Krueger
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

2.  Effects of the H3 receptor inverse agonist thioperamide on cocaine-induced locomotion in mice: role of the histaminergic system and potential pharmacokinetic interactions.

Authors:  Christian Brabant; Livia Alleva; Thierry Grisar; Etienne Quertemont; Bernard Lakaye; Hiroshi Ohtsu; Jian-Sheng Lin; Peter Jatlow; Marina R Picciotto; Ezio Tirelli
Journal:  Psychopharmacology (Berl)       Date:  2008-10-09       Impact factor: 4.530

3.  Histamine H3 receptor antagonist JNJ-39220675 modulates locomotor responses but not place conditioning by dopaminergic drugs.

Authors:  Jenni Vanhanen; Marja Kinnunen; Saara Nuutinen; Pertti Panula
Journal:  Psychopharmacology (Berl)       Date:  2014-10-12       Impact factor: 4.530

Review 4.  Histamine: an undercover agent in multiple rare diseases?

Authors:  Almudena Pino-Ángeles; Armando Reyes-Palomares; Esther Melgarejo; Francisca Sánchez-Jiménez
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

5.  Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification.

Authors:  Jakub Jończyk; Barbara Malawska; Marek Bajda
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

6.  4-Hydroxypiperidines and Their Flexible 3-(Amino)propyloxy Analogues as Non-Imidazole Histamine H₃ Receptor Antagonist: Further Structure⁻Activity Relationship Exploration and In Vitro and In Vivo Pharmacological Evaluation.

Authors:  Beata Olszewska; Anna Stasiak; Daniel McNaught Flores; Wiesława Agnieszka Fogel; Rob Leurs; Krzysztof Walczyński
Journal:  Int J Mol Sci       Date:  2018-04-19       Impact factor: 5.923

7.  Structure-Activity Relationship of Hetarylpropylguanidines Aiming at the Development of Selective Histamine Receptor Ligands.

Authors:  Steffen Pockes; David Wifling; Armin Buschauer; Sigurd Elz
Journal:  ChemistryOpen       Date:  2019-03-05       Impact factor: 2.911

8.  Organic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levels.

Authors:  Elke Schneider; François Machavoine; Jean-Marie Pléau; Anne-France Bertron; Robin L Thurmond; Hiroshi Ohtsu; Takehiko Watanabe; Alfred H Schinkel; Michel Dy
Journal:  J Exp Med       Date:  2005-08-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.